Drug intelligence / Profile preview

autologous total immunoglobulin G

Development stage: Unknown
Lead developer: Ajou University School of Medicine
Administration: Intramuscular

Overview

Autologous total IgG is an experimental, personalized biologic therapy developed by Ajou University School of Medicine. The treatment involves the purification of a patient's own total immunoglobulin G (IgG) from their plasma to a high degree of purity (≥97%) using Protein A chromatography. Administered via intramuscular injection, the therapy is hypothesized to act as an immunomodulator that stimulates or modulates T cell responses to enhance the body's immune reaction against cancer. It is currently being investigated in Phase 1/2 clinical trials for the treatment of various advanced solid tumors, including non-small cell lung cancer, gastric cancer, melanoma, and renal cell carcinoma.

Other names: autologous total IgGautologous immunoglobulin

Beyond the preview

Go deeper on autologous total immunoglobulin G.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous total immunoglobulin G.

Explore the full profile